These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Edaravone for treatment of early-stage ALS - Authors' reply. Akimoto M; Nakamura K; Lancet Neurol; 2017 Oct; 16(10):772. PubMed ID: 28920878 [No Abstract] [Full Text] [Related]
48. Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. Zhou S; Yu G; Chi L; Zhu J; Zhang W; Zhang Y; Zhang L Neurotoxicology; 2013 Sep; 38():136-45. PubMed ID: 23932983 [TBL] [Abstract][Full Text] [Related]
49. [Outcome assessment in treatment of edaravone in childhood ischemic stroke]. Osaka H; Okazaki S No To Hattatsu; 2008 Sep; 40(5):403-5. PubMed ID: 18807890 [No Abstract] [Full Text] [Related]
50. Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. Xi H; Akishita M; Nagai K; Yu W; Hasegawa H; Eto M; Kozaki K; Toba K Atherosclerosis; 2007 Apr; 191(2):281-9. PubMed ID: 16806227 [TBL] [Abstract][Full Text] [Related]
51. Edaravone, a free radical scavenger, attenuates behavioral deficits following transient forebrain ischemia by inhibiting oxidative damage in gerbils. Lu F; Nakamura T; Toyoshima T; Liu Y; Hirooka K; Kawai N; Okabe N; Shiraga F; Tamiya T; Miyamoto O; Keep RF; Itano T Neurosci Lett; 2012 Jan; 506(1):28-32. PubMed ID: 22040669 [TBL] [Abstract][Full Text] [Related]
52. Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone. Kakimoto A; Ishizaki M; Ueyama H; Maeda Y; Ueda M Medicine (Baltimore); 2021 May; 100(21):e26127. PubMed ID: 34032759 [TBL] [Abstract][Full Text] [Related]
53. Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway. Zhang D; Xiao Y; Lv P; Teng Z; Dong Y; Qi Q; Liu Z Neurol Res; 2018 Jan; 40(1):1-10. PubMed ID: 29125058 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience. Ismail II; Massoud F; Kamel WA; Al-Hashel JY Acta Neurol Belg; 2021 Dec; 121(6):1591-1597. PubMed ID: 32651875 [TBL] [Abstract][Full Text] [Related]
55. Bacterial translocation in hemorrhagic shock: Are we any wiser? Foëx BA Crit Care Med; 2005 May; 33(5):1166-7. PubMed ID: 15891366 [No Abstract] [Full Text] [Related]
56. Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo. Inokuchi Y; Imai S; Nakajima Y; Shimazawa M; Aihara M; Araie M; Hara H J Pharmacol Exp Ther; 2009 May; 329(2):687-98. PubMed ID: 19201991 [TBL] [Abstract][Full Text] [Related]
57. Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. Saini AK; Kumar H S A; Sharma SS Eur J Pharmacol; 2007 Jul; 568(1-3):164-72. PubMed ID: 17521626 [TBL] [Abstract][Full Text] [Related]
58. New modalities for the treatment of acute cardioembolic stroke. Uchiyama S Intern Med; 2006; 45(8):493-4. PubMed ID: 16702738 [No Abstract] [Full Text] [Related]
59. What is the role of free radical scavengers in acute stroke? Wadiwala MF; Sonawalla A; Kamal AK J Pak Med Assoc; 2012 May; 62(5):512-3. PubMed ID: 22755325 [No Abstract] [Full Text] [Related]